Replies to post #193524 on Biotech Values

[Rocky3]

For 2Q15, the operating margin will probably be about 55%, IMO. Applying this rate to the $70M estimate for sales and dividing by 2 gives about $19M for MNTA’s (pre-tax) take.

For a while "pre-tax" = "post-tax." Hopefully sales will be high enough in Q4 that it will matter. Hope that pricing holds up (no third player).

[Double_Bagel]

That was just off by 0.2 million!

http://seekingalpha.com/pr/14295185-momenta-pharmaceuticals-reports-second-quarter-2015-financial-results

Total revenues for the second quarter of 2015 were $44.9 million compared to $11.0 million for the same period in 2014. Total revenues for the second quarter of 2015 include $19.2 million in product revenue, which represents 50% of contractual profit earned from net sales of Glatopa by Sandoz, net of a deduction of $9.0 million in reimbursement to Sandoz of the Companys share of pre-launch Glatopa-related legal expenses.